Latest Articles
Julianne Hough Opens Up About Third Round of Egg Freezing Amid Endometriosis Battle - Music + Essentials
Julianne Hough Opens Up About Third Round of Egg Freezing Amid Endometriosis Battle Music + Essentials
Published: June 9, 2025, 8:49 p.m.
Endometriosis Pain Pipeline 2025: Mechanism of Action, Route - openPR.com
Endometriosis Pain Pipeline 2025: Mechanism of Action, Route openPR.com
Published: June 9, 2025, 8:39 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as Fir - GuruFocus
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as Fir GuruFocus
Published: June 9, 2025, 7:13 p.m.
BAEP makes endometriosis strategic plan - nationnews.com
BAEP makes endometriosis strategic plan nationnews.com
Published: June 9, 2025, 5:02 p.m.
Leveraging epigenetic aberrations in the pathogenesis of endometriosis: From DNA methylation to non-coding RNAs - Frontiers
Leveraging epigenetic aberrations in the pathogenesis of endometriosis: From DNA methylation to non-coding RNAs Frontiers
Published: June 9, 2025, 4:59 p.m.
Game-changing new tests to spot endometriosis early and spare women years of agony - Daily Mail
Game-changing new tests to spot endometriosis early and spare women years of agony Daily Mail
Published: June 9, 2025, 3:31 p.m.
Game-changing tests to spot endometriosis early stop years of agony - Daily Mail
Game-changing tests to spot endometriosis early stop years of agony Daily Mail
Published: June 9, 2025, 3:31 p.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer HealthDay
Published: June 9, 2025, 2:50 p.m.
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News GuruFocus
Published: June 9, 2025, 12:46 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace
Published: June 9, 2025, 12:43 p.m.
Link copied to clipboard!